Figure 1 | Scientific Reports

Figure 1

From: Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease

Figure 1

Novel LRRK2 kinase inhibitors are not acutely toxic to human lymphoblastoid cells. Human lymphoblastoid cells derived from healthy control or LRRK2 G2019S carriers were treated with the highest dose used in the overall study (1 μM) of the LRRK2 kinase inhibitors RA334 or RA283 and compared to DMSO treated cells. Apoptosis was assessed by Annexin-PI staining and flow cytometry. (A) Representative flow cytometry distribution of live, apoptotic or dead cells. (B) Quantification of Annexin-PI staining reveals LRRK2 kinase inhibitors do not cause toxicity relative to vehicle treated cells. Data are mean ± SEM. n = 2 biological replicates (4 cell lines total) performed at least in technical triplicate.

Back to article page